1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Butorphanol Formulation

Manufacturer or supplier’s details
Company : MSD
Address : Briahnager - Off Pune Nagar Road
Wagholi - Pune - India 412 207
Telephone : +1-908-740-4000
Emergency telephone number : +1-908-423-6000
E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use : Veterinary product

2. HAZARDS IDENTIFICATION

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

Classification
Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification
Specific target organ toxicity - single exposure (Oral) : Category 2 (Central nervous system)
Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Blood, Central nervous system)

GHS label elements
Signal word : Warning
Hazard statements : H371 May cause damage to organs (Central nervous system) if swallowed.
H373 May cause damage to organs (Blood, Central nervous system) through prolonged or repeated exposure if swallowed.

Precautionary statements : Prevention:
P260 Do not breathe mist or vapours.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
SAFETY DATA SHEET

Butorphanol Formulation

Response:
P308 + P316 IF exposed or concerned: Get emergency medical help immediately.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/container to an approved waste disposal plant.

Other hazards which do not result in classification
None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture: Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>17-(Cyclobutylmethyl)morphinan-3,14-diyl [S-[(R*,R*)]-2,3-dihydroxysuccinate</td>
<td>58786-99-5</td>
<td>&gt;= 1 - &lt; 2.5</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed: May cause damage to organs if swallowed. May cause damage to organs through prolonged or repeated exposure if swallowed.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES
SAFETY DATA SHEET

Butorphanol Formulation

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during firefighting:
Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides

Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters:
In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions:
Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling:
Do not breathe mist or vapours.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage:
Keep in properly labelled containers.
Store locked up.
Store in accordance with the particular national regulations.

Materials to avoid:
Do not store with the following product types:
Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>17-((Cyclobutyl)methyl)morphinan-3,14-diy[ S-(R°,R°)]-2,3- dihydroxy succinate</td>
<td>58786-99-5</td>
<td>TWA</td>
<td>3 µg/m³ (OEB 4)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Wipe limit 30 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures:
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Essentially no open handling permitted.
Use closed processing systems or containment technologies.
If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment

Respiratory protection:
If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type:
Particulates type

Hand protection:
Material:
Chemical-resistant gloves
Remarks:
Consider double gloving.

Eye protection:
Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a face shield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: liquid
Colour: colourless
Odour: No data available
Odour Threshold: No data available
pH: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: 100 °C
Flash point: No data available
Evaporation rate: No data available
Flammability (solid, gas): Not applicable
Flammability (liquids): No data available
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Vapour pressure: No data available
Relative vapour density: No data available
Relative density: No data available
Density: No data available
SAFETY DATA SHEET

BUTORPHANOL FORMULATION

Solubility(ies):  
Water solubility: No data available
Partition coefficient: n-octanol/water: Not applicable
Auto-ignition temperature: No data available
Decomposition temperature: No data available
Viscosity:  
Viscosity, kinematic: No data available
 Explosive properties: Not explosive
Oxidizing properties: The substance or mixture is not classified as oxidizing.
Particle size: Not applicable

10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: Can react with strong oxidizing agents.
Conditions to avoid: None known.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure: Inhalation
                        Skin contact
                        Ingestion
                        Eye contact

Acute toxicity:  
Not classified based on available information.

Product:  
Acute oral toxicity: Acute toxicity estimate: > 5,000 mg/kg
                        Method: Calculation method

Components:  
17-(Cyclobutylmethyl)morphinan-3,14-diyl [S-(R\(^{*}\),R\(^{*}\)]-2,3-dihydroxysuccinate:
Acute oral toxicity: LD50 (Mouse): 395 mg/kg
                        LD50 (Dog): > 50 mg/kg
                        LD50 (Monkey): > 50 mg/kg
Acute inhalation toxicity: Remarks: No data available

Acute dermal toxicity: Remarks: No data available

**Skin corrosion/irritation**
Not classified based on available information.

**Components:**

17-(Cyclobutylmethyl)morphinan-3,14-diy [S-{R*,R*}]-2,3-dihydroxysuccinate:
Remarks: No data available

**Serious eye damage/eye irritation**
Not classified based on available information.

**Components:**

17-(Cyclobutylmethyl)morphinan-3,14-diyl [S-{R*,R*}]-2,3-dihydroxysuccinate:
Species: Rat
Result: No eye irritation

**Skin sensitisation**
Not classified based on available information.

**Respiratory or skin sensitisation**

**Skin sensitisation**
Not classified based on available information.

**Respiratory sensitisation**
Not classified based on available information.

**Components:**

17-(Cyclobutylmethyl)morphinan-3,14-diyl [S-{R*,R*}]-2,3-dihydroxysuccinate:
Exposure routes: Dermal
Assessment: Does not cause skin sensitisation.
Result: negative

**Germ cell mutagenicity**
Not classified based on available information.

**Components:**

17-(Cyclobutylmethyl)morphinan-3,14-diyl [S-{R*,R*}]-2,3-dihydroxysuccinate:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: negative

**Carcinogenicity**
Not classified based on available information.
# SAFETY DATA SHEET

## Butorphanol Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.4</td>
<td>10.10.2020</td>
<td>918977-00010</td>
<td>23.03.2020</td>
<td>03.10.2016</td>
</tr>
</tbody>
</table>

### Components:

| 17-(Cyclobutylmethyl)morphinan-3,14-diyl \([S\-(R^*,R^*)]\)-2,3-dihydroxy succinate: |
|-------------------------------------|---------------------------------|
| **Species**                         | Rat                             |
| **Application Route**               | Oral                            |
| **Exposure time**                  | 2 Years                         |
| **Result**                          | negative                        |

| **Species**                         | Mouse                           |
| **Application Route**               | Oral                            |
| **Exposure time**                  | 2 Years                         |
| **Result**                          | negative                        |

### Reproductive toxicity

Not classified based on available information.

### Components:

| 17-(Cyclobutylmethyl)morphinan-3,14-diyl \([S\-(R^*,R^*)]\)-2,3-dihydroxy succinate: |
|-------------------------------------|---------------------------------|
| **Effects on fertility**            | Test Type: Fertility/early embryonic development |
| **Species**                         | Rat                             |
| **Application Route**               | Oral                            |
| **Fertility**                       | LOAEL: 160 mg/kg body weight    |
| **Result**                          | Effects on fertility            |

| **Effects on foetal development**   | Test Type: Embryo-foetal development |
| **Species**                         | Rat                             |
| **Application Route**               | Subcutaneous                     |
| **Developmental Toxicity**         | LOAEL: 1 mg/kg body weight       |
| **Result**                          | No teratogenic effects, Increased stillbirths |

| **Species**                         | Rabbit                          |
| **Application Route**               | Oral                            |
| **Developmental Toxicity**         | LOAEL: 30 mg/kg body weight     |
| **Result**                          | No teratogenic effects, Maternal toxicity observed., Postimplantation loss. |

| **Species**                         | Rat                             |
| **Application Route**               | Subcutaneous                     |
| **Developmental Toxicity**         | LOAEL: 0.5 mg/kg body weight    |
| **Result**                          | Maternal toxicity observed.     |

### Reproductive toxicity - Assessment

Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

### STOT - single exposure

May cause damage to organs (Central nervous system) if swallowed.
Butorphanol Formulation

Components:
17-(Cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:
Target Organs: Central nervous system
Assessment: Causes damage to organs.

STOT - repeated exposure
May cause damage to organs (Blood, Central nervous system) through prolonged or repeated exposure if swallowed.

Components:
17-(Cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:
Target Organs: Blood, Central nervous system
Assessment: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:
17-(Cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:
Species: Rat
LOAEL: 0.4 mg/kg
Application Route: Subcutaneous
Exposure time: 6 Months
Target Organs: Blood, Central nervous system

Species: Monkey
LOAEL: 0.15 mg/kg
Application Route: Intramuscular
Exposure time: 6 Months
Target Organs: Central nervous system

Species: Dog
LOAEL: 0.1 mg/kg
Application Route: Intramuscular
Exposure time: 3 Months
Symptoms: reduced body weight gain

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:
17-(Cyclobutylmethyl)morphinan-3,14-diyl [S-(R*,R*)]-2,3-dihydroxysuccinate:
Ingestion: Symptoms: Drowsiness, Sweating, Nausea, Dizziness, Vertigo, Palpitation, respiratory depression
12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

17-(Cyclobutylmethyl)morphinan-3,14-diyl \( [S-(R^*,R^*)]-2,3\)-dihydroxysuccinate:

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 38.1 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Persistence and degradability
No data available

Bioaccumulative potential
No data available

Mobility in soil
No data available

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to IMO instruments
Not applicable for product as supplied.

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:
16. OTHER INFORMATION

Further information

Date format: dd.mm.yyyy

Full text of other abbreviations

AICS - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisati

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS mate-
Material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

IN / EN